The Wegovy 0.25 mg/0.5 ml pen: what it does and what comes next

Why your prescriber starts here, not at a higher dose

Starting weight-loss treatment with the lowest available dose can feel counterintuitive. If the goal is significant weight loss, why begin at 0.25 mg? The answer is practical: semaglutide works by slowing gastric emptying and reducing appetite through GLP-1 receptor activity, and those same effects are what cause the nausea, stomach discomfort and loose stools that some people notice early on. The 0.25 mg/0.5 ml pen gives your digestive system a month to adjust before the dose rises.

Clinical trial programmes confirmed this approach. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, reached only after a structured series of monthly steps that begins exactly here, at 0.25 mg. Skipping that foundation tends to mean worse side effects and, often, people stopping treatment earlier than they needed to.

It is worth being honest with yourself at this stage: if you are not noticing much happening in the first four weeks, that is expected and correct. Your prescriber will assess progress at each review, not just at the end.

The decision your 0.25 mg pen is building toward

The question most people are actually working through when they start the 0.25 mg/0.5 ml pen is: can I tolerate this well enough to reach the doses where the clinical evidence is strongest? That is the real decision the first pen helps you and your prescriber make together.

After four weeks on 0.25 mg, the standard path moves to 0.5 mg (covered in detail on our Wegovy 0.5 mg pen page) and from there upward in roughly four-week steps. The full Wegovy dose schedule runs 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and then 2.4 mg as the standard maintenance dose, with the newer 7.2 mg pen available for eligible patients. Each step is a prescriber decision based on how you are tolerating the current dose and how your weight is responding.

A practical check worth doing in under a minute: before each weekly injection, glance at the expiry date printed on your pen and confirm it has been stored in the fridge (between 2°C and 8°C). Room-temperature storage windows exist but are limited, and our guide to what the 0.25 ml Wegovy dose involves goes into further detail, though it is the Patient Information Leaflet, not a general article, that gives the authoritative figure for your specific pen.

What side effects are most common at 0.25 mg, and when do they ease?

The most frequently reported effects at this starting dose are gastrointestinal: nausea, burping, loose stools or constipation, and sometimes fatigue or mild headaches. These tend to be most noticeable in the first week or two after starting or after a dose increase, and for most people they settle considerably by the time the next pen begins. If you want to understand what to expect as your treatment progresses, our page on moving from Wegovy 0.25 to 0.5 covers what that transition typically looks like. Eating smaller portions, avoiding very fatty meals and staying well hydrated all help.

Serious side effects are uncommon but real. The NHS semaglutide medicines page lists symptoms that should prompt urgent medical attention: severe and persistent stomach pain that reaches the back (a possible sign of pancreatitis), signs of a serious allergic reaction, or symptoms of gallbladder problems such as sudden sharp pain in the upper right abdomen. Contact a doctor or call 111 if any of those arise. You can also report unexpected effects directly to the MHRA via the Yellow Card scheme.

Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for use in people under 18. If any of these situations apply, your prescriber needs to know before treatment starts or continues.

Private access versus NHS waiting lists, what the 0.25 mg pen costs you in context

Wegovy is available on the NHS through specialist weight management services under NICE guidance (TA875), but access is tightly controlled and waiting lists in many areas are long. For people who do not meet the current NHS criteria or do not want to wait, a private prescription from a regulated UK pharmacy is the alternative.

If you are considering the private route, the Wegovy cost page explains how UK pricing is structured and what a legitimate private price should include, consultation, prescription and clinical aftercare are part of the package, not extras. You can also explore all licensed weight-loss treatments to see how Wegovy sits alongside other options.

Whatever route you take, the supply chain matters. The MHRA has warned publicly about counterfeit pens sold without a valid prescription through social media and unverified websites. Any legitimate UK pharmacy can be checked on the GPhC pharmacy register. If you cannot verify a pharmacy there, that is a clear signal to stop.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician) on the same day it is submitted. If you are ready to find out whether Wegovy is clinically suitable for you, start your free consultation and our prescribers will take it from there.